We talk with Susan Mitchell, a Harvard researcher who set out to characterize the final clinical stages of advanced dementia. There are some surprises — namely, the benefit of clear communications with patients and their families (which, come to think of it, shouldn’t come as much of a surprise at all).
Talk with us at 1-617-440-4374 or write to jelia@nejm.org.
This week’s links:
Interview:
Advanced Dementia’s Course
News summaries:
Prophylactic Acetaminophen Reduces Immunogenicity of Childhood Vaccine...
We talk with Susan Mitchell, a Harvard researcher who set out to characterize the final clinical stages of advanced dementia. There are some surprises — namely, the benefit of clear communications with patients and their families (which, come to think of it, shouldn’t come as much of a surprise at all).
Talk with us at 1-617-440-4374 or write to jelia@nejm.org.
This week’s links:
Interview:
- Advanced Dementia’s Course
News summaries:
- Prophylactic Acetaminophen Reduces Immunogenicity of Childhood Vaccines
- Nursing Home Residents See Marked Declines in Functional Status After Starting Dialysis
- Minimally Invasive vs. Open Radical Prostatectomy
The post Podcast 61: A conversation about end-stage dementia. first appeared on Clinical Conversations.
View more